Page 9 - Diabetes

New diabetes drug achieves blood sugar, weight targets faster: Research

T2D is a chronic and progressive condition in which the body does not make or use insulin normally, leading to high levels of glucose in the blood

Control of blood sugar in mothers with diabetes better for infants: Study

Research led by Caroline Crowther of the University of Auckland, New Zealand, and a team, the findings were published in the journal PLOS Medicine

Pricing regulator closely watching prices of diabetes drug going off patent

Regulator looking to cap prices of Sitagliptin, Linagliptin and combinations

Zydus Life launches generic version of Sitagliptin for type 2 diabetes

Zydus Lifesciences Ltd on Friday said it has launched the generic version of sitagliptin in India under the brand names Sitaglyn and Siglyn to address type 2 diabetes.

Going off-patent, key diabetes drug likely to get 50-70% cheaper

Merck's Sitagliptin set to lose patent this month; around 200 brands from 50 firms may enter the market

US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients

On Tuesday, the CDC, citing case reports and concerns that relapsed patients could spread the virus, issued its advisory that Paxlovid users should isolate for a second five days if symptoms rebound

Tech firm MFine helps people monitor blood pressure, glucose on smartphones

MFine has democratised health care at home by bringing these solutions on to devices that are more ubiquitous and affordable than wearables

Long Covid-induced diabetes, depression can be treated by exercise: Study

Though no medically recognized treatment exists for Long Covid, a study suggests that exercise might break cycle of inflammation that develops diabetes and depression months after a person recovers

Zydus gets regulator nod to market generic diabetes drug in American

Zydus Group on Wednesday said it has received final approval from the US health regulator to market diabetes medication Dapagliflozin tablets in the American market. The drug maker has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 5 mg and 10 mg. Dapagliflozin is used with a proper diet and exercise programme to control high blood sugar in people with type 2 diabetes. The drug also lowers the risk of heart failure in adults with type 2 diabetes with heart disease. It is also used to lower the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), death due to cardiovascular disease, and hospitalisation for heart failure in adults with chronic kidney disease. Dapagliflozin works by increasing the removal of sugar by kidneys. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad, Zydus Group stated. The group now has 328 approvals and has so far fi

Pharma company Abbott ties up with health tech firms for diabetes care

Abbott on Tuesday said it has tied up with health-tech firms like BeatO, Sugar.fit, PharmEasy, GOQii, 1MG and Zyla for diabetes care

India's diabetes care market to reach $60 bn in next 10 yrs: Report

The diabetes care market in India is expected to reach about $60 billion in the next 10 years, from approximately $17 billion in FY2021, a new report said

Statsguru: Obesity to diabetes, 6 charts explain health concerns for India

Data shows that obesity is increasingly growing among both men and women

Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

These injections will help control high blood sugar in adult and pediatric patients with type-1 diabetes and adults with type-2

IMA urges Covid vax, including booster dose if needed, for all diabetics

Noticing their vulnerabilities, IMA on Sunday demanded Covid-19 vaccination for all diabetes patients, including a third dose, if needed. The IMA on Sunday launched a campaign for early detection and mitigation of diabetes complications with organising of walkathon, marathon, screening camps, and a social media drive. The campaign also included research paper promotion among young doctors and an "intense" personal intervention at hospitals. The campaign, launched on the occasion of world Diabetes Day, will run for 10 days and will aim to reach one billion people, the Indian Medical Association (IMA) said in a statement. As part of the campaign, the IMA has joined hands with the association of Physicians of India, RSSDI, Endocrine Society, and many other niche organisations. As per the data from the 10th Edition of the IDF Diabetes Atlas, diabetes caused 6.7 million deaths in 2021, with 537 million adults (aged 20 to 79 years) around the world currently living with the condition.

Post-Covid fatigue is most prevalent in diabetes patients: Study

People with Type-2 diabetes who also suffered Covid-19 are more likely to experience severe fatigue than those who did not have the infectious disease, according to a new study released on Thursday

Germany's Boehringer, Indian pharma in legal battle over diabetes drug

The German drug maker has obtained interim injunctions against MSN Labs and Dr Reddy's Lab

NPPA fixes price caps for 12 anti-diabetic medicines

These include glimepiride tablet of strength 1 mg, with ceiling price at Rs 3.6 per tablet, while that for 2 mg is Rs 5.72 per tablet

Study finds why people with diabetes develop severe Covid-19

A recent study by a team of international clinical researchers reveals the mechanism behind cytokine storm during coronavirus infection.

Startup Sugar.fit, which aims to reverse diabetes, to raise $10 million

Health and fitness firm Cure.fit and two others to invest the funds in a deal likely to by September

Wockhardt's growth tonic: Covid vaccines add a third prong to biz strategy

In India, Wockhardt aims to make 2 billion doses of Covid-19 vaccines within the next one or two years but has not disclosed the identity of the tie-ups